flora peyvandi/X
Dec 8, 2025, 07:42
Flora Peyvandi: Anti-emicizumab Antibodies and Their Relevance in Clinical Practice
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“The development of anti-emicizumab antibodies is a rare event, particularly those with neutralizing activity. Routine monitoring should be reserved only for patients with clinical manifestations of bleeding when therapy failure is suspected.”
Title: Anti-emicizumab antibodies and their relevance in clinical practice
Authors: Carla Valsecchi, Lucia Schiavone, Sara Arcudi, Adriana Torri, Cristina Novembrino, Flora Peyvandi
Read the full article.
More posts featuring Flora Peyvandi on Hemostasis Today.
-
Dec 10, 2025, 17:22In the Fight for Hematology: Adetokunbo O’s Reflections from ASH25
-
Dec 10, 2025, 17:11Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
-
Dec 10, 2025, 16:37Arthur Allen – The New President-Elect of the Anticoagulation Forum Board of Directors
-
Dec 10, 2025, 16:29Matthew D Neal: An Oasis in the Platelet Desert?
-
Dec 10, 2025, 16:14Yashpal Singh Rawat: Fortis Memorial Research Institute Made Its Positive Mark at ASH
-
Dec 10, 2025, 14:57Elvira Grandone Announces the 1st ThrombUS+ Data Challenge
-
Dec 10, 2025, 14:18Love Preet Kalra on A Paradigm Shift in ICH
-
Dec 10, 2025, 13:37Aakanksha A: A Highlight of the Week Was Presenting Our ASH Poster
-
Dec 9, 2025, 23:37Thomas Reiser: Renew Your ISTH Membership for 2025